";s:4:"text";s:21008:"Disclosure: I am long ATRS, SLTM, ACRX. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. We believe there is merit to the current rumors surrounding AcelRx. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Subscribe to BioPharma Dive. Enclose phrases in quotes. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Go and get our Biotech Investments HOT STOCK REPORT. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. Healthcare. If you have an ad-blocker enabled you may be blocked from proceeding. Do Not Sell My Personal Information (CA Residents Only). Government. Pharma giant Pfizer recently. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. The company has already seven products on the market. That's right -- they think these 10 stocks are even better buys. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. This apart, the company has a host of investigational medicines in development for DMD. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". earnings call is. The pipeline progress has been encouraging. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. BioMarin is almost every analyst's favorite takeover candidate. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Scott has had the most success in trading/investing in smaller cap growth companies. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Politics. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. product. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. I think those could be intriguing deals for the new year. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. I am not receiving compensation for it. Analysts, on average, see scope for about 90% upside for Mirati stock. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Brian, what are some acquisitions that you'd like to. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. Invest better with The Motley Fool. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. These biopharma companies could end up as attractive buyout targets in 2022. . If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. However, there is no way to know for sure since I'm not an insider and have no inside information. *Average returns of all recommendations since inception. This therapeutic has been licensed to Swiss pharma giant Novartis. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Rumors. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Alexion Pharmaceuticals. Go and get the Biotech Investments HOT STOCK REPORT. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. All rights reserved. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. 6. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Best Penny Stocks . In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. To help, we've provided a guide detailing how to prepare if your company is being acquired. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. I don't know. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. To make the world smarter, happier, and richer. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. No. The Company submitted a Marketing Authorization Application to the. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Get biopharma news like this in your inbox daily. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . There would be some synergies on the commercial sales side. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. This conference call is no longer online, but the. "Human natural killer cell" [Micrograph]. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. ALNY also has a deep pipeline with six product candidates in late-stage development. 12. 11. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Acquisitions are back in full swing in the sector. In case of a buyout, investors often benefit of a massive premium. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Who will buy? There were a few, but not as many. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They could develop that in combination. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. BMRN briefly touched $100.13 on February 5, 2019. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). But I think there's also a good fit on Seagen's pipeline too. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. The uptake of all these products has been good. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. ";s:7:"keyword";s:26:"biotech acquisition rumors";s:5:"links";s:491:"Wreck On 107 Cutoff Greeneville Tn Today,
Jack Baldwin Ihuman,
Airbus A320 Stall Speed,
Articles B
";s:7:"expired";i:-1;}